We are live on ! Find out more
JANX icon

Janux Therapeutics

121 hedge funds and large institutions have $1.59B invested in Janux Therapeutics in 2024 Q1 according to their latest regulatory filings, with 63 funds opening new positions, 24 increasing their positions, 29 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

950% more first-time investments, than exits

New positions opened: 63 | Existing positions closed: 6

342% more capital invested

Capital invested by funds: $360M → $1.59B (+$1.23B)

89% more funds holding

Funds holding: 64121 (+57)

9.24% more ownership

Funds ownership: 72.71%81.95% (+9.2%)

17% less repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 29

43% less call options, than puts

Call options by funds: $3.76M | Put options by funds: $6.66M

Holders
121
Holders Change
+57
Holders Change %
+89.06%
% of All Funds
1.74%
Holding in Top 10
4
Holding in Top 10 Change
+4
Holding in Top 10 Change %
% of All Funds
0.06%
New
63
Increased
24
Reduced
29
Closed
6
Calls
$3.76M
Puts
$6.66M
Net Calls
-$2.9M
Net Calls Change
-$2.94M
Name Holding Trade Value Shares
Change
Change in
Stake
ASN
126
Advisory Services Network
Georgia
-$1.44K -134 Closed
Carson Wealth (CWM LLC)
127
Carson Wealth (CWM LLC)
Nebraska
+$22 +1 New

JANX Hedge Fund Activity: Q1 2024 in Review

121 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Janux Therapeutics (JANX) for Q1 2024, worth a combined $1.59B — up 342% from $360M a quarter earlier.

Buyers outnumbered sellers: 63 funds opened new JANX positions and 6 closed out — a net gain of 57 holders — while 24 added to existing stakes and 29 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $67M. The largest seller was BVF Inc, cutting an estimated $36.2M.

  • 121 institutional investors held Janux Therapeutics (JANX) as of Q1 2024, up from 64 in Q4 2023.
  • Funds reported $1.59B of Janux Therapeutics stock for Q1 2024, up 342% quarter-over-quarter.
  • 63 funds opened new Janux Therapeutics positions in Q1 2024 and 6 closed out, a net change of +57 holders.
  • The largest Janux Therapeutics buyer in Q1 2024 was Fidelity Investments, an estimated $67M added.
  • The largest Janux Therapeutics seller in Q1 2024 was BVF Inc, an estimated $36.2M sold.

Based on aggregated 13F filings for Q1 2024.